<DOC>
	<DOCNO>NCT00933985</DOCNO>
	<brief_summary>This phase I trial study side effect best dose obatoclax mesylate give together vincristine sulfate , doxorubicin hydrochloride , dexrazoxane hydrochloride treat young patient relapsed refractory solid tumor , lymphoma , leukemia . Obatoclax mesylate may stop growth cancer cell block protein need cell growth cause cell self-destruct . Drugs use chemotherapy , vincristine sulfate , doxorubicin hydrochloride , dexrazoxane hydrochloride , work different way stop growth cancer cell , either kill cell stop divide . Giving obatoclax mesylate together combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Obatoclax Mesylate , Vincristine Sulfate , Doxorubicin Hydrochloride , Dexrazoxane Hydrochloride Treating Young Patients With Relapsed Refractory Solid Tumors , Lymphoma , Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) and/or recommend Phase II dose obatoclax ( obatoclax mesylate ) administer single agent day 1 combination vincristine ( vincristine sulfate ) , doxorubicin ( doxorubicin hydrochloride ) , dexrazoxane ( dexrazoxane hydrochloride ) day 8 child refractory solid tumor . II . To define describe toxicity obatoclax administer schedule . III . To characterize pharmacokinetics obatoclax child refractory solid tumor relapse leukemia . SECONDARY OBJECTIVES : I . To preliminarily define antitumor activity obatoclax child refractory relapse solid tumor leukemias within confines Phase I study . II . To preliminarily assess leukemic blast characteristic associate obatoclax activity . III . To preliminarily assess biological activity obatoclax investigate effect cell death regulatory pathway . OUTLINE : This dose-escalation study obatoclax mesylate . STRATUM 1 ( dose-escalation ) : Patients receive obatoclax mesylate intravenously ( IV ) 3 hour day 1 8 vincristine sulfate IV , doxorubicin hydrochloride IV , dexrazoxane hydrochloride IV day 8 course 1 ( 28 day ) . Drugs administer day 1 subsequent course repeat every 21 day 1 year absence disease progression unacceptable toxicity . STRATUM 2 : Patients receive obatoclax mesylate ( start dose stratum 1 ) , vincristine sulfate , doxorubicin hydrochloride , dexrazoxane hydrochloride stratum 1 . STRATUM 3 : Patients receive obatoclax mesylate ( MTD determine stratum 1 ) , vincristine sulfate , doxorubicin hydrochloride , dexrazoxane hydrochloride stratum 1 . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Stratum 1 ( solid tumor , include lymphoma ) : patient must histologic verification malignancy original diagnosis relapse ; patient recurrent refractory solid tumor eligible , exclude primary central nervous system ( CNS ) tumor patient know CNS metastases Stratum 2 ( mixedlineage leukemia [ MLL ] + leukemia ) : patient recurrent refractory MLL+ leukemia eligible exclude patient symptomatic CNS leukemia , CNS chloromas , leptomeningeal leukemic involvement Stratum 3 ( leukemia ) : patient nonMLL+ recurrent refractory leukemia ( acute lymphoblastic leukemia [ ALL ] , acute myeloid leukemia [ AML ] chronic myeloid leukemia [ CML ] blast crisis ) eligible exclude patient symptomatic CNS leukemia , CNS chloromas , leptomeningeal leukemic involvement Stratum 1 : patient must either measurable evaluable disease Strata 2 3 : patient leukemia must &gt; 25 % blast bone marrow aspirate eligible Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life Karnofsky &gt; = 50 % patient &gt; 16 year age Lansky &gt; = 50 patient = &lt; 16 year age Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study Myelosuppressive chemotherapy : must receive within 3 week enrollment onto study ( 6 week prior nitrosourea ) ; hydroxyurea may administer prior study enrollment ; case least 24 hour must elapse last dose hydroxyurea first dose obatoclax Hematopoietic growth factor : least 7 day since completion therapy growth factor Biologic ( antineoplastic agent ) : least 7 day since completion therapy biologic agent ; agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur ; duration interval must discuss study chair Immunotherapy : least 6 week since completion type immunotherapy , e.g . tumor vaccine Monoclonal antibody : least 3 halflives since prior therapy include monoclonal antibody Radiation therapy ( XRT ) : &gt; = 2 week ( wks ) local palliative XRT ( small port ) ; &gt; = 6 month must elapse prior totalbody irradiation ( TBI ) , craniospinal XRT &gt; = 50 % radiation pelvis ; &gt; = 6 wks must elapse substantial bone marrow ( BM ) radiation Stem cell transplant rescue without TBI : evidence active graft vs. host disease &gt; = 3 month must elapse since transplant STRATUM 1 : Peripheral absolute neutrophil count ( ANC ) &gt; = 1000/mm^3 STRATUS 1 : Platelet count &gt; = 100,000/mm^3 ( transfusion independent , define receive platelet transfusion within 7 day period prior enrollment ) STRATUM 1 : Hemoglobin &gt; = 8.0 g/dL ( may receive red blood cell [ RBC ] transfusion ) STRATA 2 3 : Platelet count &gt; = 20,000/mm^3 ( may receive platelet transfusion ) STRATA 2 3 : Hemoglobin &gt; = 8.0 g/dL ( may receive RBC transfusion ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70ml/min/1.73 m^2 OR serum creatinine base age/gender follow : 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( &gt; = 16 year age ) Bilirubin ( sum conjugate + unconjugated ) &gt; = 1.5 x upper limit normal ( ULN ) age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &gt; = 110 U/L ; purpose study , ULN SGPT 45 U/L Serum albumin &gt; = 2 g/dL Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 50 % gate radionuclide study Stable neurological examination least 2 week prior study enrollment ; know &gt; grade 2 unresolved neurological toxicity All patient and/or parent legal guardian must sign write informed consent ; assent , appropriate , obtained accord institutional guideline Pregnant breastfeed woman enter study ; pregnancy test must obtain girl postmenarchal ; male female reproductive potential may participate unless agree use effective contraceptive method Growth factor support platelet white cell number function must administer within 7 day prior enrollment Patients require corticosteroid stable decrease dose corticosteroid prior 7 day Patients currently receive another investigational drug eligible Patients currently receive anticancer agent , exception hydroxyurea , eligible ; patient leukemia may receive intrathecal therapy outline Any anticonvulsant medication Patients uncontrolled infection eligible Patients opinion investigator may able comply safety monitoring requirement study eligible Patients total lifetime cumulative anthracycline dose &gt; 750 mg/m2 ( 25 mg/kg &lt; 1 year ) doxorubicin equivalent time enrollment eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>